Selling a Specialty Pharmacy in 2026: Multiples, Named Buyers, and the Operator Playbook
Quick Answer
A US specialty pharmacy in 2026 typically sells for roughly 4x to 12x EBITDA, varying by therapeutic focus, limited-distribution-drug (LDD) access, payer network status, and platform scale. By profile: a single-location community specialty pharmacy ($500k-1.5M EBITDA) goes 4x-6x; a regional multi-state specialty pharmacy with LDD access ($1.5-4M EBITDA) goes 5x-7x; a mid-size specialty platform ($4-12M EBITDA, multi-state, broad LDD access, payer-network in-network) goes 6x-9x; a premium scale specialty pharmacy ($12M+ EBITDA, multi-state with URAC + ACHC accreditation, rare-disease or oncology focus, named manufacturer relationships) reaches 8x-12x+ EBITDA. Active buyers include Walgreens Specialty (WBA, retail giant with specialty division), CVS Specialty (CVS, integrated with Caremark PBM), Cigna Accredo (Cigna, the largest US specialty pharmacy by some measures), Optum Specialty Pharmacy (UnitedHealth Group, post Diplomat Specialty Pharmacy acquisition 2019), Avita Specialty Pharmacy (PE-backed, 340B-focused), Senderra (Optum-owned), PANTHERx Rare (Optum, rare-disease specialist), AllianceRx Walgreens Prime (Walgreens + Prime Therapeutics), Therigy (Mercer Advisors), Soleo Health (Court Square Capital), CSI Pharmacy (Linden Capital), plus PE sponsors (Court Square Capital, Linden Capital, H.I.G. Capital, Webster Equity Partners, Frazier Healthcare). The biggest multiple drivers are LDD access (the moat), therapeutic-class focus (rare disease, oncology, hemophilia premium to general chronic-disease specialty), payer-network in-network status (esp. PBM specialty networks like ESI, Caremark, OptumRx), URAC + ACHC accreditation, modern operating system (PocketRx, PharmacyKeeper, ComputerRx, Liberty Software), and 340B participation if applicable. Buyer-paid M&A advisory (CT Strategic Partners) costs the seller nothing.
If you own a specialty pharmacy in 2026, the M&A market is heavily consolidated and dominated by vertically-integrated payer-owned specialty pharmacies. CVS Specialty (CVS Health/Caremark PBM), Cigna Accredo, Walgreens Specialty (WBA), and Optum Specialty (UnitedHealth Group) account for the majority of US specialty pharmacy revenue through payer integration. Independent specialty pharmacies face narrowing network access but those with named LDD access and therapeutic specialty focus continue to command interest from strategic and PE buyers (Soleo Health/Court Square, CSI Pharmacy/Linden).
What the asset is worth depends on three things: (1) LDD (limited-distribution-drug) access and named manufacturer relationships, (2) therapeutic specialty focus (rare disease, oncology, hemophilia are premium subsegments), and (3) payer-network in-network status (especially PBM specialty networks: ESI, Caremark, OptumRx, Humana). This guide covers real multiples by profile, the named buyers transacting, and the operator-level diligence buyers will run.
What this guide covers
- Specialty pharmacy multiples 2026: 4x-6x for single-location community, 5x-7x for regional multi-state with LDD access, 6x-9x for mid-size platforms with broad LDD + payer network, 8x-12x+ for premium scale with rare-disease or oncology focus.
- Active buyers (payer-integrated giants): Walgreens Specialty (WBA), CVS Specialty (CVS), Cigna Accredo, Optum Specialty Pharmacy (UnitedHealth Group), AllianceRx Walgreens Prime. Specialty/rare-disease: PANTHERx Rare (Optum), Senderra (Optum). PE-backed: Avita Specialty Pharmacy, Soleo Health (Court Square), CSI Pharmacy (Linden Capital).
- PE sponsor activity: Court Square Capital (Soleo Health), Linden Capital (CSI Pharmacy), H.I.G. Capital, Webster Equity Partners, Frazier Healthcare, plus multiple healthcare-services PE funds.
- Multiple drivers: LDD access (the moat), therapeutic-class focus (rare disease, oncology, hemophilia premium), PBM specialty network in-network status, URAC + ACHC accreditation, modern operating system, 340B participation if applicable.
- Things that compress the multiple: no LDD access, narrow PBM network access, no therapeutic specialty focus, weak accreditation, single-state without growth path, dependence on a single payer or manufacturer, open OIG / state-board issues, legacy operating systems.
- Sellers pay nothing on CT Strategic Partners’ buyer-paid advisory.
Named specialty pharmacy M&A transactions (2019-2025)
| Target | Buyer | Year | What it tells us |
|---|---|---|---|
| Diplomat Specialty Pharmacy | Optum (UnitedHealth Group) | 2019 | Major specialty pharmacy consolidation; established Optum as a top-3 specialty pharmacy. |
| PANTHERx Rare | Optum (UnitedHealth Group) | 2022 | Rare-disease specialty pharmacy acquired by Optum; rare-disease subsegment validated. |
| Senderra | Optum (UnitedHealth Group) | 2024 | Continued Optum specialty pharmacy consolidation. |
| Soleo Health continued growth | Court Square Capital | 2022-2025 | PE-backed specialty pharmacy continues regional rollups. |
| CSI Pharmacy expansion | Linden Capital | 2022-2025 | PE-backed specialty pharmacy continues regional rollups. |
| Avita Specialty Pharmacy | PE-backed (340B-focused) | 2022-2025 | PE-backed 340B-focused specialty pharmacy continues regional expansion. |
The named buyer landscape
Payer-integrated specialty pharmacy giants
- Cigna Accredo — Cigna-integrated, one of the largest US specialty pharmacies.
- CVS Specialty (CVS Health) — integrated with Caremark PBM.
- Optum Specialty Pharmacy (UnitedHealth Group) — post Diplomat 2019, PANTHERx 2022, Senderra 2024.
- Walgreens Specialty (Walgreens Boots Alliance) — retail giant with specialty division.
- AllianceRx Walgreens Prime (Walgreens + Prime Therapeutics).
Rare-disease and specialty-focused subsegment leaders
- PANTHERx Rare (Optum) — rare-disease specialist.
- Senderra (Optum) — ultra-rare and specialty.
PE-backed specialty pharmacies
- Soleo Health (Court Square Capital) — specialty pharmacy / specialty infusion.
- CSI Pharmacy (Linden Capital) — specialty pharmacy + home infusion.
- Avita Specialty Pharmacy (PE-backed) — 340B-focused.
- Multiple PE-backed regional specialty pharmacies operating across the US.
PE sponsors active in this space
- Court Square Capital (Soleo Health), Linden Capital (CSI Pharmacy), H.I.G. Capital, Webster Equity Partners, Frazier Healthcare, plus multiple healthcare-services PE funds.
What each buyer will pay for vs. what they reject
- Will pay premium for: named LDD (limited-distribution-drug) access, therapeutic-class focus (rare disease, oncology, hemophilia, multiple sclerosis, HIV, hepatitis C), PBM specialty network in-network status (ESI, Caremark, OptumRx, Humana Pharmacy Solutions), URAC + ACHC accreditation, modern operating system (PocketRx, PharmacyKeeper, ComputerRx, Liberty Software, Datascan), 340B participation where applicable, named manufacturer relationships, multi-state licensure footprint.
- Will compress or reject: no LDD access, narrow PBM network access (out-of-network with major payers), no therapeutic specialty focus (general retail dispensing), weak accreditation, open OIG/state-board investigation, single-state without growth path, dependence on a single payer or single manufacturer above 25%, legacy operating systems, undocumented inventory turn or chain-of-custody.
The operator-level KPI playbook buyers will diligence
Therapeutic class and drug mix
- Therapeutic class mix: Oncology %, rare disease %, multiple sclerosis %, hepatitis C %, HIV %, hemophilia %, rheumatology %, dermatology %, etc.
- Top drugs by revenue: Document top-20 drugs by revenue and gross margin.
- LDD access: Number of limited-distribution drugs the operation has access to; named manufacturer relationships (e.g., specialty distributors AmerisourceBergen, Cardinal, McKesson Specialty).
- Average reimbursement per prescription.
- Drug-cost ratio: Cost of drugs as % of revenue.
Payer network
- PBM specialty network in-network status: Express Scripts (ESI), CVS Caremark, OptumRx, Humana Pharmacy Solutions, Prime Therapeutics, MedImpact, plus regional PBMs.
- Manufacturer hub status: Some manufacturers designate specific specialty pharmacies as hubs.
- Payer concentration: No single payer above 25%.
Accreditation and regulatory
- URAC specialty pharmacy accreditation.
- ACHC specialty pharmacy accreditation.
- NABP / Joint Commission accreditation as applicable.
- State board of pharmacy licensure in every state of operation.
- USP 797 / 800 compliance for sterile and hazardous compounding.
- 340B participation if applicable; covered-entity relationships documented.
Clinical and adherence operations
- Patient adherence/persistence metrics: 90-day, 180-day, 1-year refill rates by drug.
- Clinical pharmacist staffing.
- Patient counseling protocols.
- Side effect management programs.
- Prior authorization workflow.
Operating system and technology
- Pharmacy management system: PocketRx, PharmacyKeeper, ComputerRx, Liberty Software, Datascan, Rx30, McKesson EnterpriseRx.
- Specialty pharmacy clinical module: Therigy STM, Asembia ARMS, ScriptPro.
- Patient portal and engagement.
- Manufacturer-data reporting: Real-time data feeds to manufacturer hubs and drug brands.
RCM and financial
- Days in AR: <45 days is healthy.
- Denial rate: <8% first-pass on specialty claims.
- Drug-cost ratio trend.
- Inventory turn: Specialty drug inventory turns slowly; document aged inventory.
Dangers and traps in specialty pharmacy M&A
1. No LDD access
LDD (limited-distribution-drug) access is the durable moat in specialty pharmacy. Without it, the pharmacy competes on price for commodity specialty drugs.
2. Narrow PBM network access
Payer-integrated specialty pharmacy giants increasingly steer prescriptions in-network. Independent pharmacies that lose network access lose revenue. Document network status by PBM.
3. Single payer or manufacturer concentration
Above 25% single-payer or single-manufacturer concentration is a real risk.
4. State board of pharmacy and DEA
Open state-board or DEA investigations are deal-killers.
5. USP 797 / 800 compliance gaps
Sterile and hazardous compounding has detailed compliance requirements.
6. 340B compliance (if applicable)
340B audit exposure and covered-entity relationship documentation are diligence focus areas.
7. Anti-kickback / Stark exposure on manufacturer relationships
Manufacturer hub status arrangements, rebate structures, and patient assistance programs all require compliance review.
8. Aged inventory and drug-cost ratio
Specialty drug inventory turns slowly; document aged inventory and writeoff history.
Our POV on specialty pharmacy M&A in 2026
Specialty pharmacy is heavily consolidated and dominated by payer-integrated giants (Cigna Accredo, CVS Specialty, Optum Specialty Pharmacy, Walgreens Specialty). Independent specialty pharmacies face narrowing network access, but those with named LDD access and therapeutic specialty focus continue to command interest from PE buyers (Court Square Capital, Linden Capital, H.I.G. Capital, Webster Equity, Frazier Healthcare). Multiples thinner for non-specialty than rare-disease/oncology focused.
Preparing your specialty pharmacy for sale: 12-18 months out
- Get multi-year audited financials.
- Document LDD access. Every named limited-distribution-drug relationship.
- Develop therapeutic specialty focus. Rare disease, oncology, hemophilia premium.
- Confirm PBM specialty network in-network status.
- Document accreditation cleanliness. URAC, ACHC, NABP, state board, USP 797/800.
- Document 340B compliance. If applicable.
- Document adherence/persistence metrics by drug.
- Modernize the operating system. Specialty pharmacy clinical module integration.
- Run a competitive process. Walgreens Specialty (WBA), CVS Specialty (CVS), Cigna Accredo, Optum Specialty (UNH), Soleo Health (Court Square), CSI Pharmacy (Linden), Avita Specialty, plus PE sponsors directly.
Free, No Email Required
Get a personalized valuation in 90 seconds
Answer six quick questions and we’ll give you a sector-adjusted EBITDA multiple range plus the specific factors driving your number up or down.
Open the Valuation Tool →The five pillars of how CT Acquisitions works
Buyer pays our fee. Founders never write a check.
No engagement letter. No upfront cost. No exclusivity contract.
Search funders, family offices, lower-middle-market PE, strategics.
Confidential introductions to the right buyers. No bidding war.
Not 9-12 months. Not 18 months. Months, not years.
No Pitch · No Pressure
Ready to start a confidential conversation?
Tell us about your business. We’ll tell you what it’s likely worth, whether we have qualified buyers in our network, and what the next 60-120 days could look like. No engagement letter. No retainer. Walk at any time.
Start a Confidential Conversation →Frequently asked questions
What is the typical multiple for a specialty pharmacy in 2026?
Single-location community specialty pharmacies ($500k-1.5M EBITDA) typically sell at 4x-6x EBITDA. Regional multi-state with LDD access ($1.5-4M EBITDA) go 5x-7x. Mid-size specialty platforms with broad LDD and payer network ($4-12M EBITDA) go 6x-9x. Premium scale specialty pharmacies ($12M+ EBITDA, multi-state, URAC + ACHC accredited, rare-disease or oncology focus, named manufacturer relationships) reach 8x-12x+.
Who are the active buyers of specialty pharmacies right now?
Payer-integrated giants: Cigna Accredo, CVS Specialty (CVS Health), Optum Specialty Pharmacy (UnitedHealth Group, post Diplomat 2019 + PANTHERx 2022 + Senderra 2024), Walgreens Specialty (WBA), AllianceRx Walgreens Prime. Rare-disease specialists: PANTHERx Rare (Optum), Senderra (Optum). PE-backed: Soleo Health (Court Square Capital), CSI Pharmacy (Linden Capital), Avita Specialty Pharmacy. PE sponsors: Court Square Capital, Linden Capital, H.I.G. Capital, Webster Equity Partners, Frazier Healthcare.
What hurts a specialty pharmacy’s valuation most?
No LDD (limited-distribution-drug) access, narrow PBM network access (out-of-network with major payers like ESI/Caremark/OptumRx), no therapeutic specialty focus, weak URAC/ACHC accreditation, open OIG or state-board investigations, single payer or manufacturer concentration above 25%, USP 797/800 compliance gaps, legacy operating systems, and anti-kickback exposure on manufacturer relationships.
What is LDD access and why does it matter so much?
LDD (limited-distribution-drug) means the manufacturer has agreed to supply specific specialty drugs through your pharmacy in a restricted distribution network. LDD access is the durable moat in specialty pharmacy — without it, you compete on price for commodity specialty drugs. Premium specialty pharmacies have named LDD relationships with manufacturers for high-cost therapies in oncology, rare disease, and biologics.
Why are payer-integrated specialty pharmacies (Cigna Accredo, CVS Specialty, Optum Specialty) so dominant?
PBM (pharmacy benefit manager) integration allows the payer to steer specialty prescriptions to their captive specialty pharmacy. This vertical integration captures both the dispensing margin and the PBM administrative margin. Independent specialty pharmacies face narrowing network access as payers prefer their captive operations. Premium independent specialty pharmacies survive by offering specialized therapeutic expertise or LDD access that the giants don’t have.
Do I have to pay a broker fee?
No. CT Strategic Partners runs a buyer-paid M&A advisory model. The seller pays nothing. The buyer pays the success fee at closing.
How long does it take to sell a specialty pharmacy?
Once you go to market with a buyer-paid advisor, a typical process runs 6-9 months from initial outreach to closing, with regulatory and accreditation diligence extending the timeline. Add 12-18 months of preparation work before going to market.
When should I start preparing if I plan to sell in 2027 or 2028?
12-18 months before going to market is the right window. Highest-leverage pre-sale work: document LDD access, develop therapeutic specialty focus (rare disease, oncology, hemophilia), confirm PBM network status, ensure URAC/ACHC accreditation cleanliness, document 340B compliance if applicable.
Related research
- How to sell an infusion therapy business
- How to sell a clinical laboratory
- How to sell a DME business
- How to sell a hospice business
- How to sell a home health agency
- How to sell an urgent care center
- Healthcare business valuation
- Which industries is PE buying most in 2026
- Private equity value creation
- Business broker alternative
About the Author
Christoph Totter is the founder of CT Acquisitions, a buy-side partner headquartered in Sheridan, Wyoming. We work directly with 76+ buyers, search funders, family offices, lower middle-market PE, and strategic consolidators, including direct mandates with the largest home services consolidators that other intermediaries can’t access. The buyers pay us when a deal closes, not the seller. No retainer, no exclusivity, no contract until close. Connect on LinkedIn · Get in touch